Clinical Trials Logo
  1. Home
  2. Thromboembolism
  3. NCT01420809

Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection

Thromboembolism Clinical Trial

Official title:
Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection

Clinical Trial Summary

This post-marketing surveillance study was designed to collect and assess the information on proper use of fondaparinux injection, such as the safety and efficacy under actual use conditions, in subjects undergoing orthopedic surgery of the lower limb at high risk of developing venous thromboembolism.

(ARIXTRA® is a trademark of the GlaxoSmithKline group of companies.)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01420809
Study type Observational
Source GlaxoSmithKline
Contact
Status Completed
Phase N/A
Start date September 2007
Completion date August 2009
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Active, not recruiting NCT05563883 - Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
Terminated NCT02475187 - Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
Recruiting NCT00982514 - Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008 N/A
Terminated NCT00206089 - Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events Phase 3
Completed NCT00014352 - Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer Phase 2
Completed NCT00000614 - Prevention of Recurrent Venous Thromboembolism (PREVENT) Phase 3
Active, not recruiting NCT05656963 - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Completed NCT02935751 - Apixaban Discontinuation Prior to Major Surgery
Terminated NCT02579122 - REVIparin-BRIDging-in a General Practice Setting in GErmany
Completed NCT01696760 - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology N/A
Completed NCT00986154 - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Phase 3
Terminated NCT00662688 - Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer Phase 3
Completed NCT00260988 - A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery Phase 2/Phase 3
Terminated NCT00031837 - Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer Phase 3
Completed NCT03877770 - DVT After Cardiac Procedure
Completed NCT00024297 - Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters N/A
Recruiting NCT06118957 - Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery Phase 2
Completed NCT04686981 - Endovascular thromBectomy of Acute Mesentery Vessels Occlusion Hybrid With Emergent Laparoscopic Surgery